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Abstract
In systemic sclerosis (SSc), peripheral vasculopathy is
characterized by a progressive and irreversible loss of
capillaries following endothelial cell injury, due to
defects in both vascular repair and expected increase
in new vessel growth (angiogenesis). The discovery of
key molecular targets may help to develop the most
effective therapeutic strategy for the SSc-related
vasculopathy. A pathway worth targeting in SSc may
include vascular endothelial growth factor, 165b
isoform, an endogenous angiogenesis inhibitor
abnormally expressed and released by different cell
types, including activated endothelial cells and platelets.
Dysregulated expression of several proangiogenic and
antiangiogenic factors has been implicated in the
dysfunction of angiogenesis in systemic sclerosis (SSc).
Into this complex scenario comes the study recently
published in Arthritis Research & Therapy by Hirigoyen
et al. [1], who report new data implicating an inhibitory
splice variant of vascular endothelial growth factor
(VEGF)-A, namely VEGF165b, in the inhibition of angio-
genesis by platelets in SSc. These findings are part of an
intriguing chain of data as several studies have shown
that VEGF-A, one of the most potent promoters of
angiogenesis, is markedly increased in SSc skin and
circulation despite clear evidence of an insufficient
angiogenic response [2, 3]. This was considered the
“SSc paradox” until it became evident recently that early
studies could not distinguish between proangiogenic
VEGF165 and antiangiogenic VEGF165b isoforms generated
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by alternative splicing in VEGF-A pre-mRNA [4]. In most
pathologic angiogenic conditions, such as cancers,
VEGF165 predominates. On the contrary, this crucial
balance between isoforms shifts in favor of the expression
of VEGF165b in SSc (Fig. 1) [4, 5]. VEGF165b appears
selectively overexpressed in different cell types of SSc
dermis, including endothelial cells (ECs), fibroblasts, and
perivascular mononuclear inflammatory cells [5]. In vitro
studies further revealed that SSc dermal microvascular
endothelial cells (MVECs) express and release elevated
levels of VEGF165b [5]. Moreover, the increased VEGF165b
plasma levels in SSc correlate with the extent of nailfold
capillary architectural derangement and loss, suggesting
their potential utility as a biomarker reflecting disease
severity [6]. In this context, the study by Hirigoyen et al.
[1] adds new valuable information showing that, in SSc,
platelets store high levels of VEGF165b. It could therefore
be suggested that platelets may be a major source of
circulating VEGF165b in SSc, in particular following their
activation on contact with the injured endothelium.
The discovery of VEGF165b clearly adds a new
fundamental figure in the complex crossroad of the mech-
anisms underlying dysfunctional angiogenesis in SSc.
Binding of VEGF165 to vascular endothelial growth factor
receptor (VEGFR)-2 induces VEGFR-2 internalization and
activates signaling pathways that trigger EC proliferation,
survival, and migration which are necessary for angio-
genesis. VEGF165b binds to VEGFR-2 with the same
affinity as VEGF165, but binding of VEGF165b results in an
insufficient tyrosine phosphorylation/activation of VEGFR-2
and incomplete downstream signaling (Fig. 1) [4]. Owing
to increased levels of VEGF165b, SSc-MVECs show re-
duced VEGFR-2 phosphorylation and impaired capillary
morphogenesis in vitro [5]. Accordingly, the angiogenic
performance of SSc-MVECs can be improved by cotreat-
ment with recombinant VEGF165 and anti-VEGF165b
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Fig. 1 Schematic illustration of the mechanisms impairing VEGF-A/VEGFR-2 angiogenic signal in SSc. Angiogenesis tightly depends on the balance of
proangiogenic VEGF165 and antiangiogenic VEGF165b isoforms. In angiogenic conditions, VEGF165 predominates, whereas in SSc the balance shifts to
favor the expression of the VEGF165b splice variant in different cell types, such as ECs, platelets, fibroblasts, and mononuclear inflammatory cells. In ECs,
binding of VEGF165 to both VEGFR-2 and NRP1 coreceptor activates VEGFR-2 phosphorylation and multiple downstream signaling pathways that are
necessary for angiogenesis. Moreover, uPAR interacts with VEGFR-2 and recruits LRP-1 to VEGFR-2, which induces internalization of VEGF165-bound
VEGFR-2, a key step in the proangiogenic signal. In SSc, both a switch from proangiogenic VEGF165 to antiangiogenic VEGF165b, which is unable to bind
NRP1, and concomitant NRP1 downregulation due to Fli1 transcription factor deficiency result in an insufficient tyrosine phosphorylation/activation of
VEGFR-2 and incomplete or transient downstream signaling along with a differential intracellular trafficking of VEGFR-2 toward the degradative
pathway, ultimately leading to impaired angiogenesis. In SSc ECs, MMP-12-mediated cleavage/inactivation of uPAR may further impair the VEGF-A/
VEGFR-2 system. EC endothelial cell, Fli1 Friend leukemia integration 1, LRP-1 low-density lipoprotein receptor-related protein 1, MMP-12 matrix
metalloproteinase-12, NRP1 neuropilin-1, SSC systemic sclerosis, uPAR urokinase-type plasminogen activator receptor, VEGF vascular endothelial growth
factor, VEGFR vascular endothelial growth factor receptor
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Hirigoyen et al. [1], when healthy dermal MVECs were in-
cubated with SSc platelet releasates containing elevated
levels of VEGF165b, capillary-like tube formation was
significantly inhibited compared with cells treated with
control platelet releasates.It is known that the nontyrosine kinase receptor
neuropilin-1 (NRP1) acts as a VEGFR-2 coreceptor in
angiogenesis [7]. VEGF165b antiangiogenic function is
thought to be mechanistically related to the lack of
NRP1 coreceptor binding [4]. In fact, upon binding of
VEGF165b to VEGFR-2, the absence of NRP1 cosignaling
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teasomal degradation [4]. In SSc, besides VEGF165b over-
expression, concomitant NRP1 downregulation because
of Friend leukemia integration 1 (Fli1) transcription fac-
tor deficiency may further disturb VEGF-A/VEGFR-2
signaling [8]. Finally, in this complex scenario the
urokinase-type plasminogen activator receptor (uPAR),
an angiogenic orchestrator acting via both VEGF-A-
dependent and VEGF-A-independent mechanisms, may
play a significant role because uPAR inactivation re-
presents a master factor challenging angiogenesis in SSc
[2, 9]. uPAR–VEGFR-2 interaction is crucial for VEGFR-2
internalization and proangiogenic signaling in ECs [10].
Of note, VEGF-A-induced angiogenesis is prevented in
uPAR-deficient mice, a recently proposed animal model of
SSc [9, 10]. uPAR inactivation/deficiency may thus con-
tribute substantially to VEGF-A/VEGFR-2 system abnor-
malities in SSc (Fig. 1).
Taken together, considerable evidence suggests that
uncontrolled expression of the antiangiogenic VEGF165b
isoform may take center stage in this crowded crossroad
to angiogenesis in SSc. It remains to be elucidated
whether the targeting of VEGF165b and/or VEGF-A pre-
mRNA splicing machinery might represent a promising
therapeutic strategy to promote effective angiogenesis in
SSc patients. As pointed out in the article by Hirigoyen
et al. [1], a better understanding of how platelets trans-
port and deliver uncontrolled levels of VEGF165b to the
injured endothelium might disclose a novel pathway
contributing to the SSc-related peripheral vasculopathy.
Whether this mechanism is a priority pathway worth
targeting warrants further studies.
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